Is ProQR Therapeutics N.V. (PRQR) stock halal?
Thresholds exceeded under all standards, and the strict view excludes it.
This verdict follows the median view, that of AAOIFI Standard No. 21. It is based on the financial statements for the fiscal year ended 12/31/2025.
The ratios
| Criterion | Measure | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.3% of total assets | 30% | within threshold |
| Interest-bearing investments | 81.9% of total assets | 30% | threshold exceeded |
| Impermissible income | 14.5% of revenue | 5% | threshold exceeded |
Standard: Total assets, 30% threshold.
Margin to threshold and trend
| Item | Ratio (fiscal year end) | Threshold (Total assets, 30% threshold) | Margin | Change since year end | Estimated ratio |
|---|---|---|---|---|---|
| Interest-bearing debt | 4.3% | 30% | 25.7% | not read | — |
| Interest-bearing investments | 81.9% | 30% | −51.9% | not read | — |
No quarterly financial statements after fiscal year end, or inconsistent reading: the change is not shown. "On watch" flags a permitted company whose estimated ratio reaches the threshold, or is within 5 points of the threshold and rising. This is neither a forecast nor advice.
The three views
- Median view, our reference : the company is excluded.
- Strictest view : the company is excluded, because it borrows or invests at interest.
- Most lenient view : the company is excluded.
Business activity
Pharmaceutical Preparations (SIC code 2834)
Financial statements read
Fiscal year ended 12/31/2025, in millions of euros. Source: SEC EDGAR: annual reports of ProQR Therapeutics N.V..
What could not be verified
- Valeur de marché : non déclarée dans ce type de rapport, donc ratio AAOIFI non calculé ; la tolérance est jugée sur le total des actifs.
- Activity classified from the SEC sector code, without reading the annual report.
- Figures read automatically and not reviewed by a human.
Status history
Loading history…
General information: neither investment advice nor a fatwa. Verdict calculated by published rules, from financial statements read automatically and not reviewed by a human. Read the methodology